Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (SHA:603811)
China · Delayed Price · Currency is CNY 10.24
-0.21 (-2.01%)
Jun 11, 2026, 2:05 PM CST
SHA:603811 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 826.28 | 810.87 | 712.31 | 669.61 | 653.25 | 693.45 |
Other Revenue | 1.48 | 1.48 | 2.06 | 2.01 | 1.72 | 0.52 |
| 827.75 | 812.35 | 714.37 | 671.63 | 654.97 | 693.96 | |
Revenue Growth (YoY) | 10.82% | 13.72% | 6.36% | 2.54% | -5.62% | -8.46% |
Cost of Revenue | 257.06 | 254.26 | 225.17 | 248.45 | 217.8 | 208.98 |
Gross Profit | 570.69 | 558.09 | 489.2 | 423.17 | 437.17 | 484.99 |
Selling, General & Admin | 335.11 | 326.72 | 308.66 | 246.92 | 269.61 | 280.27 |
Research & Development | 49.6 | 44.44 | 47.08 | 47.14 | 44.3 | 39.72 |
Other Operating Expenses | 16.03 | 14.28 | 12.34 | 7.46 | 7.77 | 10.7 |
Operating Expenses | 401.04 | 385.07 | 365.77 | 302.46 | 321.83 | 331.21 |
Operating Income | 169.66 | 173.02 | 123.43 | 120.71 | 115.34 | 153.78 |
Interest Expense | -2.73 | -3.83 | -11.09 | -15.26 | -9.13 | -4.52 |
Interest & Investment Income | 27.59 | 33.33 | 46.28 | 67.12 | 49.08 | 31.87 |
Currency Exchange Gain (Loss) | -0.35 | -0.35 | 0.01 | -0.17 | 3.45 | 5.36 |
Other Non Operating Income (Expenses) | 0.76 | 0.22 | -0.07 | -0.31 | -0.11 | -0.99 |
EBT Excluding Unusual Items | 194.93 | 202.39 | 158.56 | 172.1 | 158.62 | 185.49 |
Impairment of Goodwill | - | - | - | - | -2.42 | -2.92 |
Gain (Loss) on Sale of Investments | - | - | - | - | -3.55 | 10.69 |
Gain (Loss) on Sale of Assets | 22.26 | 21.06 | 69.17 | -0 | 0.06 | -0.45 |
Asset Writedown | -3.2 | -4.77 | -24 | -7.47 | -0.41 | -0.5 |
Other Unusual Items | 6.77 | 5.16 | 14.4 | 9.44 | 11.53 | 5.19 |
Pretax Income | 220.77 | 223.84 | 218.13 | 174.06 | 163.84 | 197.5 |
Income Tax Expense | 25.55 | 26.38 | 17.35 | 12.01 | 2.66 | 26.27 |
Earnings From Continuing Operations | 195.22 | 197.47 | 200.79 | 162.05 | 161.18 | 171.23 |
Minority Interest in Earnings | -1.61 | -2.35 | -0.09 | 0.85 | 0.4 | -0.43 |
Net Income | 193.61 | 195.12 | 200.7 | 162.9 | 161.58 | 170.8 |
Net Income to Common | 193.61 | 195.12 | 200.7 | 162.9 | 161.58 | 170.8 |
Net Income Growth | -9.45% | -2.78% | 23.21% | 0.81% | -5.39% | 3.42% |
Shares Outstanding (Basic) | 317 | 320 | 329 | 326 | 330 | 328 |
Shares Outstanding (Diluted) | 317 | 320 | 329 | 326 | 330 | 328 |
Shares Change (YoY) | -3.62% | -2.78% | 0.99% | -1.20% | 0.67% | 0.59% |
EPS (Basic) | 0.61 | 0.61 | 0.61 | 0.50 | 0.49 | 0.52 |
EPS (Diluted) | 0.61 | 0.61 | 0.61 | 0.50 | 0.49 | 0.52 |
EPS Growth | -6.05% | - | 22.00% | 2.04% | -6.02% | 2.82% |
Free Cash Flow | 219.3 | 234.99 | 145.83 | 123.93 | -86.92 | 9.38 |
Free Cash Flow Per Share | 0.69 | 0.73 | 0.44 | 0.38 | -0.26 | 0.03 |
Dividend Per Share | 0.300 | 0.300 | 0.250 | 0.200 | 0.179 | 0.179 |
Dividend Growth | 20.00% | 20.00% | 25.00% | 11.98% | - | - |
Gross Margin | 68.95% | 68.70% | 68.48% | 63.01% | 66.75% | 69.89% |
Operating Margin | 20.50% | 21.30% | 17.28% | 17.97% | 17.61% | 22.16% |
Profit Margin | 23.39% | 24.02% | 28.09% | 24.25% | 24.67% | 24.61% |
Free Cash Flow Margin | 26.49% | 28.93% | 20.41% | 18.45% | -13.27% | 1.35% |
EBITDA | 263.63 | 267.22 | 218.56 | 198.04 | 176.89 | 208.45 |
EBITDA Margin | 31.85% | 32.90% | 30.59% | 29.49% | 27.01% | 30.04% |
D&A For EBITDA | 93.97 | 94.2 | 95.13 | 77.32 | 61.55 | 54.67 |
EBIT | 169.66 | 173.02 | 123.43 | 120.71 | 115.34 | 153.78 |
EBIT Margin | 20.50% | 21.30% | 17.28% | 17.97% | 17.61% | 22.16% |
Effective Tax Rate | 11.57% | 11.78% | 7.95% | 6.90% | 1.62% | 13.30% |
Revenue as Reported | 827.75 | 812.35 | 714.37 | 671.63 | 654.97 | 693.96 |
Advertising Expenses | - | 4.88 | 3.85 | 1.81 | 0.89 | 1.41 |